Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Jun 2021)

Diagnosing Biliary Strictures

  • Yasuki Hori, MD,
  • Suresh T. Chari, MD,
  • Yoshihisa Tsuji, MD, PhD,
  • Naoki Takahashi, MD,
  • Dai Inoue, MD,
  • Phil A. Hart, MD,
  • Takeshi Uehara, MD,
  • Masayasu Horibe, MD,
  • Satoshi Yamamoto, MD,
  • Akira Satou, MD,
  • Lizhi Zhang, MD,
  • Kenji Notohara, MD,
  • Itaru Naitoh, MD,
  • Takahiro Nakazawa, MD

Journal volume & issue
Vol. 5, no. 3
pp. 535 – 541

Abstract

Read online

Biliary strictures caused by inflammation or fibrosis lead to jaundice and cholangitis which often make it difficult to distinguish malignant strictures. In cases when malignancy cannot be excluded, surgery is often performed. The concept of immunoglobulin G4 (IgG4)–related sclerosing cholangitis (SC) as a benign biliary stricture was recently proposed. The high prevalence of the disease in Asian countries has resulted in multiple diagnostic and treatment guidelines; however, there is need to formulate a standardized diagnostic strategy among various countries considering the utility, invasiveness, and cost-effectiveness. We evaluated accuracies of various diagnostic modalities for biliary strictures comparing pathology in the Delphi meetings which were held in Rochester, MN. The diagnostic utility for each modality was graded according to the experts, including gastroenterologists, endoscopists, radiologists, and pathologists from the United States and Japan. Diagnostic utility of 10 modalities, including serum IgG4 level, noninvasive imaging, endoscopic ultrasound, endoscopic retrograde cholangiopancreatography–related diagnostic procedures were advocated and the reasons were specified. Serum IgG4 level, noninvasive imaging, diagnostic endoscopic ultrasound and intraductal ultrasonography under endoscopic retrograde cholangiopancreatography were recognized as useful modalities for the diagnosis. The information in this article will aid in the diagnosis of biliary strictures particularly for distinguishing IgG4–SC from cholangiocarcinoma and/or primary SC.